CD34⁺ selected stem cell boosts can improve poor graft function after paediatric allogeneic stem cell transplantation

Area of Science:

• Hematology
• Transplantation Immunology
• Pediatric Oncology

Background:

• Poor graft function (PGF) is a serious complication following hematopoietic stem cell transplantation (HSCT).
• Donor stem cell boosts (SCBs) are a potential therapeutic strategy for PGF.
• Limited data exists on the efficacy and safety of SCBs from alternative donors in pediatric PGF.

Purpose of the Study:

• To evaluate the safety and efficacy of CD34+ selected peripheral blood stem cell boosts (SCBs) in pediatric patients with PGF.
• To assess the impact of SCBs on hematological recovery, transfusion requirements, and immune reconstitution.
• To determine the incidence of graft-versus-host disease (GvHD) after SCB administration.

Main Methods:

• Retrospective analysis of 50 pediatric patients with PGF receiving 61 SCBs from matched unrelated or mismatched related donors.
• Analysis of hematological parameters (neutrophils, red blood cells, platelets) and transfusion requirements before and after SCBs.
• Assessment of lymphocyte subsets and GvHD incidence.

Main Results:

• Significant increases in neutrophil counts and lymphocyte subsets (CD3+, CD4+, CD19+, CD56+) were observed within 8 weeks.
• Reduced red blood cell and platelet transfusion requirements were noted.
• 78.8% of patients resolved at least one cytopenia, with 36.5% achieving complete hematological response.
• Low incidence of de novo acute GvHD (6%) with no grade IV or chronic GvHD. A trend towards better overall survival was observed in responders.

Conclusions:

• CD34+ selected SCBs from alternative donors are safe and effective in treating pediatric PGF.
• SCBs promote hematological recovery and reduce transfusion dependence.
• Further research is needed to elucidate the long-term impact on immune reconstitution and survival.